| [1] |
Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American thoracic society[J]. Clin Infect Dis, 2016, 63(5): e61-e111.
|
| [2] |
Gross AE, Van Schooneveld TC, Olsen KM, et al. Epidemiology and predictors of multidrug-resistant community-acquired and health care-associated pneumonia[J]. Antimicrob Agents Chemother, 2014, 58(9): 5262-5268.
|
| [3] |
Chalmers JD, Rother C, Salih W, et al. Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis[J]. Clin Infect Dis, 2014, 58(3): 330-339.
|
| [4] |
Melsen WG, Rovers MM, Groenwold RH, et al. Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies[J]. Lancet Infect Dis, 2013, 13(8): 665-671.
|
| [5] |
Giantsou E, Liratzopoulos N, Efraimidou E, et al. Both early-onset and late-onset ventilator-associated pneumonia are caused mainly by potentially multiresistant bacteria[J]. Intensive Care Med, 2005, 31(11): 1488-1494.
|
| [6] |
Schuetz P, Briel M, Christ-Crain M, et al. Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis[J]. Clin Infect Dis, 2012, 55(5): 651-662.
|
| [7] |
Schuetz P, Muller B, Christ-Crain M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections[J]. Evid Based Child Health, 2013, 8(4): 1297-1381.
|
| [8] |
Nseir S, Favory R, Jozefowicz E, et al. Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study[J]. Crit Care, 2008, 12(3): R62.
|
| [9] |
Martin-Loeches I, Povoa P, Rodriguez A, et al. Incidence and prognosis of ventilator-associated tracheobronchitis (TAVeM): a multicentre, prospective, observational study[J]. Lancet Respir Med, 2015, 3(11): 859-868.
|
| [10] |
Rello J, Sa-Borges M, Correa H, et al. Variations in etiology of ventilator-associated pneumonia across four treatment sites: implications for antimicrobial prescribing practices[J]. Am J Respir Crit Care Med, 1999, 160(2): 608-613.
|
| [11] |
Namias N, Samiian L, Nino D, et al. Incidence and susceptibility of pathogenic bacteria vary between intensive care units within a single hospital: implications for empiric antibiotic strategies[J]. J Trauma, 2000, 49(4): 638-645.
|
| [12] |
Tsai D, Lipman J, Roberts JA. Pharmacokinetic/pharmacodynamic considerations for the optimization of antimicrobial delivery in the critically ill[J]. Curr Opin Crit Care, 2015, 21(5): 412-420.
|
| [13] |
Chuang Y C, Cheng C Y, Sheng W H, et al. Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis[J]. BMC Infect Dis, 2014, 14(1): 102.
|
| [14] |
Montravers P, Dupont H, Bedos JP, et al. Tigecycline use in critically ill patients: a multicentre prospective observational study in the intensive care setting[J]. Intensive Care Med, 2014, 40(7): 988-997.
|
| [15] |
Chaari A, Pham T, Mnif B, et al. Colistin-tigecycline versus colistin-imipenem-cilastatin combinations for the treatment of Acinetobacter baumannii ventilator-acquired pneumonia: a prognosis study[J]. Intensive Care Med, 2015, 41(11): 2018-2019.
|
| [16] |
Burkhardt O, Rauch K, Kaever V, et al. Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint[J]. Int J Antimicrob Agents, 2009, 34(1): 101-102.
|
| [17] |
Dimopoulos G, Poulakou G, Pneumatikos I A, et al. Short- vs long-duration antibiotic regimens for ventilator-associated pneumonia: a systematic review and meta-analysis[J]. Chest, 2013, 144(6): 1759-1767.
|
| [18] |
Pugh R, Grant C, Cooke R P, et al. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults[J]. Cochrane Database Syst Rev, 2015, 8(8): CD007577.
|
| [19] |
Leone M, Bechis C, Baumstarck K, et al. De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial[J]. Intensive Care Med, 2014, 40(10): 1399-1408.
|